Reported total revenue of $5.94 million for 2025, a 14% decrease from $6.93 million in 2024. Net loss widened to $7.16 million in 2025 compared to $4.30 million in 2024. Recorded a $2.5 million impairment charge on its investment in Boumarang, Inc. Operating expenses increased to $11.39 million, driven by the impairment charge. Cash and cash equivalents were $2.69 million as of December 31, 2025. The company is currently trading on OTC Markets following suspension from Nasdaq on May 13, 2026.